BRAF and ependymoma: Those calls that would have been covered primarily represented SNVs in well-described oncogenes or tumor suppressors (covered by the TSO500 panel), common fusion variants such as BRAF-KIAA1549 in pilocytic astrocytoma (covered by the TSO500 panel’s RNA component) or CNAs as assessed by FISH currently at our institution (eg, 1q analysis in ependymomas using the same FISH assay that is also commonly used in the workup of oligodendroglioma).